Polycystic ovary syndrome: Rotterdam criteria, phenotypes & life-stage management (International Guideline 2023)

A woman in your fertility clinic has had irregular cycles since menarche, clinical hyperandrogenism, obesity, and polycystic ovaries on ultrasound. She is exhausted, anxious, and desperate to conceive. Your job is to confirm the diagnosis with the right test, exclude the mimics before labelling her, then walk the evidence-based ladder — lifestyle, letrozole, and an OHSS-aware IVF pathway if needed — while never losing sight of her cardiometabolic and psychological future. The Rotterdam framework and the 2023 International Guideline exist precisely to stop doctors calling the symptom a diagnosis and reaching for clomiphene first.^[1][2]

Overview and definition

PCOS is the commonest endocrine disorder of reproductive-age women — prevalence around one in ten using Rotterdam criteria, rising with ethnicity — and the leading cause of anovulatory infertility.^[5] It is a syndrome, not a single disease: a cluster of ovulatory dysfunction, androgen excess, and a characteristic ovarian morphology, set against a backdrop of insulin resistance and chronic low-grade inflammation that does not disappear at menopause.^[5][14]

The defining act of every consultation is the structured application of the Rotterdam criteria after exclusion of mimics. The syndrome has no cure; the phenotype shifts across the life course. The clinician's job is to treat the symptom in front of the woman today and to set up the surveillance that protects her tomorrow.^[2][11]

^{[2] [5] [7] [8]}

References16ShowHide

1. [1]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 2004.PMID 14711538
2. [2]Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril, 2023.PMID 37589624
3. [3]Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med, 2014.PMID 25006718
4. [4]Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril, 2018.PMID 30033227
5. [5]Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic ovary syndrome. Nat Rev Dis Primers, 2024.PMID 38637590
6. [6]Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril, 2016.PMID 27530062
7. [7]Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update, 2014.PMID 24688118
8. [8]Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update, 2018.PMID 29590375
9. [9]Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev, 2022.PMID 36165742
10. [10]Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev, 2007.PMID 17253562
11. [11]Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 2013.PMID 24151290
12. [12]Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril, 2012.PMID 22153789
13. [13]Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab, 2006.PMID 16940456
14. [14]McCartney CR, Marshall JC. Clinical practice. Polycystic ovary syndrome. N Engl J Med, 2016.PMID 27406348
15. [15]Cooney LG, Dokras A. Cardiometabolic Risk in Polycystic Ovary Syndrome: Current Guidelines. Endocrinol Metab Clin North Am, 2021.PMID 33518188
16. [16]Bahri Khomami M, Shorakae S, Hashemi S, et al. Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nature communications, 2024.PMID 38965226